QURE Dec 2023 20.000 call
- GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees. The Company granted equity awards to 42 employees as a material inducement to commencing their employment. In the aggregate, those employees received 98,900 restricted share units and options to purchase 90,500 ordinary
- Motley Fool
Why Shares of uniQure Are Dropping Tuesday
Shares of uniQure (NASDAQ: QURE) were down more than 11% as of 1:06 p.m. on Tuesday after the gene-therapy company announced that the Food and Drug Administration (FDA) had cleared its investigational new drug (IND) application for AMT-260, a treatment for refractory mesial temporal lobe epilepsy (MTLE). The disease is a chronic neurologic disorder, considered the most common form of focal epilepsy (which affects one side of the brain). At one point on Tuesday morning, the stock fell to a 52-week low of $7.40.
- GlobeNewswire
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
Clinical trial initiation expected in the fourth quarter of 2023LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy (MTLE). AMT-260
